Inhibition of serine/threonine protein phosphatase PP1 protects cardiomyocytes from tunicamycin-induced apoptosis and I/R through the upregulation of p-eIF2α

Chunlei Liu, Yunyun He, Xin Li, Ruijun Li, Kunlun He, Lili WangInternational Journal of Molecular Medicine 2013 · DOI

Abstract

The serine/threonine protein phosphatase PP1 mediates the dephosphorylation of phosphorylated eukaryotic translation initiation factor 2 subunit α (p-eIF2α), a central regulator of protein synthesis. This study investigated the protective effects of PP1-12, a PP1 inhibitor, against tunicamycin (TM)-induced apoptosis in cultured cardiomyocytes and in an in vivo model of ischemia/reperfusion (I/R) injury. Results indicate that PP1-12 protects cell viability, induces eIF2α phosphorylation, and downregulates pro-apoptotic markers like CHOP and cleaved caspase-12, effectively reducing myocardial infarction area.

Introduction

Cardiomyocytes are highly susceptible to damage from ischemia/reperfusion (I/R) injury, which triggers severe Endoplasmic Reticulum (ER) stress. This stress leads to the accumulation of misfolded proteins and eventually initiates programmed cell death (apoptosis). A critical regulator in this pathway is the eukaryotic translation initiation factor 2 subunit α (eIF2α). When phosphorylated (p-eIF2α), it transiently inhibits protein synthesis, allowing the cell to recover from ER stress. However, the enzyme Protein Phosphatase 1 (PP1) dephosphorylates p-eIF2α, terminating this protective signal. This study explores PP1-12 as a novel pharmacological agent to inhibit PP1 and sustain the protective effects of p-eIF2α.

Methods and Materials

Chemical Synthesis and Screening

Researchers synthesized 95 molecules based on the structure of salubrinal, a known but toxic PP1 inhibitor. Through structure-activity relationship (SAR) studies, PP1-12 was identified as a potent candidate with improved solubility and lower toxicity.

Chemical structure of the PP1 inhibitor, PP1-12.

Experimental Models

  • In Vitro: Neonatal rat cardiomyocytes were treated with Tunicamycin (TM) to induce ER stress. Cells were pre-treated with varying concentrations of PP1-12 (0.3, 1, and 3 µmol/l). Cell viability was measured via ATP bioluminescence.
  • In Vivo: Adult Sprague-Dawley rats underwent 30 minutes of left anterior descending coronary artery (LAD) ligation followed by 2 hours of reperfusion. Treatment groups received 1, 3, or 10 mg/kg/day of PP1-12.

Results

PP1-12 Sustains eIF2α Phosphorylation

Western blot analysis confirmed that PP1-12 treatment significantly increased the levels of p-eIF2α in cardiomyocytes exposed to TM. By preventing the dephosphorylation of eIF2α, PP1-12 maintains the cell's adaptive stress response.

Western blot analysis showing that PP1-12 induces eIF2α phosphorylation in TM-treated cardiomyocytes.

Protection Against Apoptosis and Tissue Damage

In cellular models, PP1-12 (3 µmol/l) reduced the expression of the pro-apoptotic protein CHOP by approximately 50%. In the animal model, the most significant protection was observed at the 10 mg/kg/day dose. The myocardial infarct area was reduced from 20.7% in the vehicle group to just 4.5% in the high-dose PP1-12 group. Furthermore, PP1-12 treatment led to a decrease in cleaved caspase-12, a marker specifically associated with ER-stress-induced apoptosis.

Discussion

The findings demonstrate that PP1-12 effectively protects cardiomyocytes from both chemical-induced ER stress and physiological I/R injury. The primary mechanism involves the inhibition of PP1, which prevents the dephosphorylation of p-eIF2α and subsequently downregulates the CHOP/caspase-12 apoptotic pathway.

While these results are promising, further research is needed to map the exact molecular docking of PP1-12 and assess potential off-target effects on other phosphatases. Long-term safety profiles and efficacy in larger mammalian models are necessary steps before clinical translation can be considered.

Summary updated

Abstract

The serine/threonine protein phosphatase PP1 mediates the dephosphorylation of phosphorylated eukaryotic translation initiation factor 2 subunit α (p-eIF2α), which is a central regulator of protein synthesis. In the present study, we examined the protective effects of PP1-12 (an inhibitor of the serine/threonine protein phosphatase PP1) against tunicamycin (TM)-induced apoptosis in cultured cardiomyocytes in vitro, as well as in an in vivo model of ischemia/reperfusion (I/R) injury in rat hearts. Neonatal cardiomyocytes cultured from the ventricles of the hearts of 1-day-old Wistar rats were exposed to various concentrations of PP1-12 (0.3, 1 and 3 µmol/l) for 30 min, followed by treatment with TM for 36 h. Cell viability was assessed by adenosine triphosphate (ATP) bioluminescence, and the results revealed that pre-treatment with PP1-12 protected cell viability. Western blot analysis revealed that PP1-12 induced eIF2α phosphorylation and immuncytochemistry indicated that PP1-12 downregulated the expression of C/EBP homologous protein (CHOP), which is related to apoptosis. PP1-12 suppressed cell apoptosis, with maximum protective effects displayed at the concentration of 3 µmol/l. For the in vivo experiments, male Sprague-Dawley rats were randomly divided into 5 groups: i) sham-operated; ii) vehicle (I/R + DMSO); iii) I/R + 1 mg/kg/day PP1-12; iv) I/R + 3 mg/kg/day PP1-12; and v) I/R + 10 mg/kg/day PP1-12. PP1-12 reduced the expression of cleaved caspase-12 and increased the phosphorylation of eIF2α, as revealed by western blot analysis. By calculating the apoptotic index (AI), we found that 10 mg/kg/day PP1-12 exerted the most pronounced anti-apoptotic effect. The infarction area was significantly decreased following treatment with this concentration of PP1-12, as revealed by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Taken together, these data suggest that PP1-12 protects cardiomyocytes from TM- and I/R-induced apoptosis, and this effect is achieved at least in part through the inhibition of cell apoptosis and the induction of eIF2α phosphorylation.
BibTeX
@article{liu2013inhibition,
  author = {Chunlei Liu and Yunyun He and Xin Li and Ruijun Li and Kunlun He and Lili Wang},
  title = {{Inhibition of serine/threonine protein phosphatase PP1 protects cardiomyocytes from tunicamycin-induced apoptosis and I/R through the upregulation of p-eIF2α}},
  journal = {International Journal of Molecular Medicine},
  year = {2013},
  doi = {10.3892/ijmm.2013.1603},
}
Figure